Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
After years in the wilderness, the UK cell therapy specialist Reneuron could be about to seal a deal with a big US player.